SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and reports of heavy leveraged-position liquidations are driving the conversation, with traders debating whether the move marks capitulation or signals more downside. Some see a buying opportunity and expect a bounce, while others cite weak support and fear of further crypto-market losses.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention after a sharp slide alongside Bitcoin and the broader crypto market, with traders pointing to market-wide selling rather than a confirmed XRP-specific catalyst. The break below a key psychological level has fueled fears of further losses, while other traders see an oversold dip and are accumulating.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a steep selloff alongside the broader crypto market, with traders pointing to prolonged weakness and fresh lows. The conversation is largely bearish, with fears of further declines competing with dip-buying and calls to hold for a recovery.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with traders citing Bitcoin weakness and forced liquidations alongside wider risk-off pressure and macro concerns. Sentiment is split between calls that the decline may be capitulation and expectations of further losses, while some traders are buying the dip.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention after traders linked its sharp rally to Nvidias involvement in the Hedera Council and Hederas presence in Nvidias Open Agent Safety Platform. The community is split between viewing the AI association as a meaningful catalyst and calling the move hype or a sell-the-news pump as the token pulls back.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention amid a steep pullback from recent highs, with traders discussing weakening support, possible liquidations and broader crypto-market pressure. The community is split between calling the drop an oversold buying opportunity and expecting more downside; some also point to Zcashs privacy features and network upgrades as reasons for longer-term optimism.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.16792499 USD and is down -4.07 over the last 24 hours. It is currently trading on 1752 active market(s) with $304,416,326.91 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

Cardanos steep selloff is driving widespread bearish frustration, with some traders tying the loss of confidence to Charles Hoskinsons statement that the networks roadmap is complete and future progress depends on community governance and applications. Others are buying the dip and anticipating a rebound, leaving the conversation split between fears of further losses and hopes for recovery.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,493,507.45679271 with 591,519,914.8768357 in circulation. The last known price of Solana is 77.75210106 USD and is down -4.52 over the last 24 hours. It is currently trading on 1189 active market(s) with $3,771,510,230.13 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a sharp broader crypto selloff, with traders noting heavy downside pressure and a break below a closely watched support area as Bitcoin and other major tokens also fall. The community is split between buying the dip and expecting further declines, with some attributing the weakness to political or security concerns but no single explanation emerging as consensus.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 159.21664083 USD and is down -1.76 over the last 24 hours. It is currently trading on 414 active market(s) with $110,625,382.40 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

Quant is drawing attention after a steep selloff alongside broader crypto weakness, with traders debating whether the pullback has further to run or is a buying opportunity. Many are accumulating on weakness based on the long-term tokenized-banking and Clearing House thesis, while skeptics question the tokens near-term demand before the network goes live.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,571,868.045494 in circulation. The last known price of Stellar is 0.14587805 USD and is down -1.99 over the last 24 hours. It is currently trading on 848 active market(s) with $216,910,874.56 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for a sharp slide amid broader crypto weakness, with traders focused on persistent selling and its failure to hold recent levels. Bearish posts call it a continuing breakdown, while others are buying the dip and arguing that Stellars tokenization and DTCC-related prospects may support the longer-term case despite muted price action.

statis crypto Watchlist

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday...

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.


Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

Bearish Sentiment

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Gilead Sciences, Inc.

NASDAQ Biotechnology

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

NBI News